Reviewing the Rationale for Strategic Shareholdings and Reducing Them
First written in FY2019. 3 of 7 entries say "Advanced", first in FY2020. Latest entry: FY2026.
- FY2026RaisedAnnual report
「Unlisted shares 4 230,011 Acquired shares to build and strengthen collaborative relationships with startup companies, with the aim of creating new businesses in the medical and healthcare fields」
While continuing to review the rationale for its policy-held shares, the Company acquired 4 startup holdings for ¥230.011 million to create new businesses in the medical and healthcare fields. - FY2025Acquisition of unlisted shares for IT collaborationAnnual report
「Unlisted shares 1 50,000 Acquired shares to build and strengthen a collaborative relationship with a company specializing in research and development, with the aim of creating new businesses in the IT field」
While continuing its policy of reviewing the rationale for policy-held shares, the Company acquired unlisted shares for ¥50 million to create new businesses in the IT field and collaborate with a research and development company. - FY2023Continued review of the rationale for shareholdings and acquisition of unlisted shares for collaborationAnnual report
「In accordance with this policy, during the fiscal year the Company reviewed the rationale for its policy-held shares at a Board of Directors meeting held on 15 April 2022.」
The Company continued reviewing the rationale for its policy-held shares. During the fiscal year, it made no sales of listed shares and acquired unlisted shares for ¥30 million to build and strengthen collaborative relationships for the development of new functional polymer synthesis technologies. - FY2022AdvancedAnnual report
「During the fiscal year, the Company reviewed the rationale for its policy-held shares at a Board of Directors meeting held on 16 April 2021 and is working to reduce its holdings.」
The Company continued reviewing its policy-held shares. During the fiscal year, it sold 4 listed holdings while acquiring unlisted shares to create new businesses in the medical and healthcare fields. - FY2021AdvancedAnnual report
「Shares other than unlisted shares 11 458,090」
The Board of Directors reviewed the rationale for the policy-held shares. During the fiscal year, the Company sold 11 holdings for total proceeds of ¥458.090 million. The scale of the disposals increased from the previous fiscal year. - FY2020AdvancedAnnual report
「In accordance with this policy, during the fiscal year the Company reviewed the rationale for its policy-held shares at a Board of Directors meeting held on 27 May 2019 and is working to reduce its holdings.」
The Board of Directors reviewed the rationale for the policy-held shares. The Company sold 6 holdings for total proceeds of ¥148.021 million, while acquiring unlisted shares to pursue collaboration in the healthcare sector. - FY2019First statedAnnual report
「The Company regularly reviews the rationale for holding shares from the perspectives of strategic necessity and effectiveness, transaction history, and the returns and risks associated with shareholdings, and will reduce holdings whose rationale has become less compelling.」
For shareholdings intended to maintain and strengthen business relationships and create new business opportunities, separately identified for the first time the policy of regularly reviewing their rationale and reducing holdings whose significance has diminished.